Skip to Content

Hartford Healthcare C HGHCX

Medalist Rating as of | See Hartford Funds Investment Hub
  • NAV / 1-Day Return 26.62  /  +0.26 %
  • Total Assets 1.2 Bil
  • Adj. Expense Ratio
    2.050%
  • Expense Ratio 2.050%
  • Distribution Fee Level Average
  • Share Class Type Level Load
  • Category Health
  • Investment Style Large Growth
  • Min. Initial Investment 2,000
  • Status Open
  • TTM Yield
  • Turnover 32%

USD | NAV as of Mar 18, 2024 | 1-Day Return as of Mar 18, 2024, 10:18 PM GMT+0

Morningstar’s Analysis HGHCX

Will HGHCX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

A compelling, diversified healthcare option.

Analyst Andrew Redden

Andrew Redden

Analyst

Summary

A deep team and proven approach make Hartford Healthcare a worthwhile offering.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings HGHCX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 43.0
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Eli Lilly and Co

9.75 111.9 Mil
Healthcare

UnitedHealth Group Inc

7.35 84.4 Mil
Healthcare

Merck & Co Inc

6.30 72.3 Mil
Healthcare

Danaher Corp

3.87 44.4 Mil
Healthcare

Stryker Corp

2.85 32.6 Mil
Healthcare

Boston Scientific Corp

2.80 32.1 Mil
Healthcare

Vertex Pharmaceuticals Inc

2.66 30.5 Mil
Healthcare

HCA Healthcare Inc

2.59 29.7 Mil
Healthcare

Thermo Fisher Scientific Inc

2.49 28.6 Mil
Healthcare

Centene Corp

2.29 26.3 Mil
Healthcare